TickerFacts.

A business in context

BMRN research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-09-02 · 0001628280-26-060572

  2. 8-K · Current report

    Report date 2026-08-31 · 0001193125-26-377696 · Items 8.01

  3. 8-K · Current report

    Report date 2026-08-30 · 0001193125-26-375275 · Items 1.01,7.01,9.01

  4. 8-K · Current report

    Report date 2026-08-17 · 0001193125-26-354780 · Items 1.01,7.01,9.01

  5. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001048477-26-000016

  6. 8-K · Current report

    Report date 2026-08-06 · 0001048477-26-000015 · Items 2.02,9.01

  7. 8-K/A · Current report

    Report date 2026-04-27 · 0001048477-26-000011 · Items 8.01,9.01

  8. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040922

  9. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040920

  10. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040918

  11. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040916

  12. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040914

  13. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040911

  14. 4 · Ownership change

    Report date 2026-06-02 · 0001628280-26-040909

  15. 8-K · Current report

    Report date 2026-06-02 · 0001628280-26-040812 · Items 5.02,5.07

  16. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001048477-26-000008

  17. 8-K · Current report

    Report date 2026-05-04 · 0001048477-26-000006 · Items 2.02,9.01

  18. 8-K · Current report

    Report date 2026-04-27 · 0001193125-26-179243 · Items 1.01,2.01,2.03,7.01,9.01

  19. 8-K · Current report

    Report date 2026-04-23 · 0001193125-26-173770 · Items 8.01

  20. DEF 14A · Proxy statement

    Report date 2026-06-02 · 0001628280-26-026290

  21. 8-K · Current report

    Report date 2026-03-16 · 0001193125-26-107314 · Items 8.01

  22. 10-K · Annual report

    Report date 2025-12-31 · 0001048477-26-000004

  23. 8-K · Current report

    Report date 2026-02-23 · 0001048477-26-000002 · Items 2.02,9.01

  24. 8-K · Current report

    Report date 2026-02-12 · 0001193125-26-048736 · Items 1.01,2.03,7.01,9.01

  25. 8-K · Current report

    Report date 2026-01-29 · 0001193125-26-029401 · Items 7.01,9.01

  26. 8-K · Current report

    Report date 2026-01-26 · 0001193125-26-021718 · Items 2.02,7.01,8.01,9.01

  27. 8-K · Current report

    Report date 2026-01-12 · 0001193125-26-010508 · Items 2.02,9.01

  28. 8-K · Current report

    Report date 2025-12-19 · 0001193125-25-327828 · Items 8.01

  29. 8-K · Current report

    Report date 2025-12-19 · 0001193125-25-325856 · Items 1.01,7.01,9.01

  30. 8-K · Current report

    Report date 2025-12-11 · 0001193125-25-322704 · Items 5.02

  31. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001048477-25-000107

  32. 8-K · Current report

    Report date 2025-10-27 · 0001048477-25-000104 · Items 2.02,9.01

  33. 8-K · Current report

    Report date 2025-10-07 · 0001048477-25-000101 · Items 2.02

  34. 8-K · Current report

    Report date 2025-08-05 · 0001048477-25-000098 · Items 5.02

  35. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001048477-25-000090

  36. 8-K · Current report

    Report date 2025-08-04 · 0001048477-25-000088 · Items 2.02,9.01

  37. 8-K · Current report

    Report date 2025-07-30 · 0001048477-25-000086 · Items 5.02

  38. 8-K · Current report

    Report date 2025-05-20 · 0001193125-25-125040 · Items 5.02,5.07

  39. 8-K · Current report

    Report date 2025-05-16 · 0001193125-25-121296 · Items 1.01,7.01,9.01

  40. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001048477-25-000051

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 1 transaction rows1SGrant / award: 9 transaction rows9AExercise / conversion: 0 transaction rows0MTax / exercise payment: 1 transaction rows1FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

11 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-02
2026-06-04
Countouriotis AthenaA · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
Walbert Timothy PA · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
Ho MaykinA · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
HOMBACH ROBERT J.A · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
Enyedy Mark JA · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
Dere Willard HA · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
CLARK IAN TA · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
Bodem Barbara W.A · Grant / award
Acquired
Common Stock7490.00.0
2026-06-02
2026-06-04
ANDERSON ELIZABETH MA · Grant / award
Acquired
Common Stock7490.00.0
2026-05-20
2026-05-21
Hubbard CristinF · Tax / exercise payment
Disposed
Common Stock2318.050.2
2026-05-07
2026-05-11
Friberg Gregory RS · Sale
Disposed
Common Stock3281.053.85

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001048477BIOMARIN PHARMACEUTICAL INC
BioMarin (United Kingdom)

Showing 1 of 1 imported Wikidata subsidiary claims. Additional aliases appear below.

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
NSLL8ITTRR0J5HEMR848
GLEIF legal name
BIOMARIN PHARMACEUTICAL INC.
Entity / LEI registration status
ACTIVE / ISSUED
Reference data updated
2025-12-18T12:56:46Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • BioMarin Pharmaceutical · alias · wikidata
  • BioMarin (United Kingdom) · subsidiary · wikidata
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$2.85B$3.04B
2023-12-31$2.42B$2.65B
2022-12-31$2.10B$2.39B
2021-12-31$1.85B$2.27B
2020-12-31$1.86B$2.40B
2019-12-31$1.70B$2.23B
2018-12-31$1.49B$1.98B
2017-12-31$1.31B$1.79B

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗